the India data has been weighing upon the share price. That's the bearish argument. The bullish one is that the FDA accepted the NDA even with the India data.
Accepting and approving are 2 totally different matters. I can't see the FDA giving full and unconditional approval to anything but a perfectly executed study with top line results. We shall see.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.